The online version of this article (https://doi.org/10.1186/s12888-018-1600-7) contains supplementary material, which is available to authorized users.
Approximately 3% of people receiving opioid substitution therapy (OST) in the UK manage to achieve abstinence from prescribed and illicit drugs within three years of commencing treatment. Involvement of families and wider social networks in supporting psychological treatment may be an effective strategy in facilitating recovery, and this pilot study aimed to evaluate the impact of a social network-focused intervention for patients receiving OST.
A two-site, open feasibility trial randomised patients receiving OST for at least 12 months but still reporting illicit opiate use in the past 28 days to one of three treatments: 1) treatment as usual (TAU), 2) Brief Social Behaviour and Network Therapy (B-SBNT) + TAU, or 3) Personal Goal Setting (PGS) + TAU. The two active interventions consisted of 4 sessions. There were 3 aims: 1) test the feasibility of recruiting OST patients to a trial of B-SBNT, and following them up over 12 months; 2) test the feasibility of training clinicians to deliver B-SBNT; 3) test whether B-SBNT reduces heroin use 3 and 12 months after treatment, and to explore potential mediating factors. The primary outcome for aim 3 was number of days of heroin use in the past month, and a range of secondary outcome measures were specified in advance (level of drug dependence, mental health, social satisfaction, therapist rapport, treatment satisfaction, social network size and support).
A total of 83 participants were randomised, and 70 (84%) were followed-up at 12 months. Fidelity analysis of showed that B-SBNT sessions were clearly distinguishable from PGS and TAU sessions, suggesting it was possible to train clinical staff to an adequate level of competence.
No significant differences were found between the 3 intervention arms in the primary or secondary outcome measures. Attendance at psychosocial treatment intervention sessions was low across all three arms (44% overall).
Patients receiving OST can be recruited into a trial of a social network-based intervention, but poor attendance at treatment sessions makes it uncertain whether an adequate dose of treatment was delivered. In order to achieve the benefits of psychosocial interventions, further work is needed to overcome poor engagement.
ISRCTN Trial Registration Number: ISRCTN22608399.
Date of registration: 27/04/2012. Date of first randomisation: 14/08/2012.
Additional file 1: Minimum, maximum, and mean session duration in minutes by trial arm. A comparison of the treatment session lengths between the three trial arms. (DOCX 16 kb)12888_2018_1600_MOESM1_ESM.docx
Additional file 2: Mean ratings for item frequency, quality and number of maps used per session by study arm. Each audio-recorded treatment session was rated by two independent raters using a standardised measure of fidelity for SBNT. This file presents data from this measure, as well as information about the number of node-link maps produced in each session. (DOCX 14 kb)12888_2018_1600_MOESM2_ESM.docx
Additional file 3: Inter-rater reliability for frequency and quality ratings. Each session was rated by the two independent raters, and inter-rater reliability was assessed using Intra Class Correlations to assess the degree that coders provided consistency in their ratings of the frequency and quality items across sessions. (DOCX 16 kb)12888_2018_1600_MOESM3_ESM.docx
Best D, George S, Day E. The development of the drug treatment system in England. In: Day E, editor. Clinical topics in addiction. London: RCPsych; 2007. p. 14–28.
HM Government. Drug strategy 2010. Reducing demand, restricting supply, building recovery: supporting people to live a drug free life. London: Home Office; 2010.
McKeganey N, Bloor M, Robertson M, Neale J, MacDougall J. Abstinence and drug abuse treatment: results from the drug outcome research in Scotland study. Drugs Educ Prev Policy. 2006;13(6):537–50. CrossRef
Day E, Mitcheson L. Psychosocial interventions in OST services: does the evidence provide a case for optimism or nihilism? Addiction. 2017;113(8):1329–36. CrossRef
Drummond DC, Kouimtsidis C, Reynolds M, Russell I, Godfrey C, McCusker M, Coulton S, Parrott S, Davis P, Tarrier N et al: The effectiveness and cost effectiveness of cognitive behaviour therapy for opiate misusers in methadone maintenance treatment: a multicentre randomised controlled trial (UKCBTMM). Final report to the Department of Health Research and Development Directorate. In. London: Department of Health; 2004.
Zywiak WH, Neighbors CJ, Martin RA, Johnson JE, Eaton CA, Rohsenow DJ. The important people drug and alcohol interview: psychometric properties, predictive validity, and implications for treatment. J Subst Abus Treat. 2009;36:321–30. CrossRef
Centre for Social Justice. Green paper on criminal justice and addiction. London: The Centre for Social Justice; 2010.
National Treatment Agency for Substance Misuse. NTA policy on involvement of users and family members. London: NTA; 2008.
National Treatment Agency for Substance Misuse. NTA business plan 2010–11. London: NTA; 2010.
The Betty Ford Institute Consensus Panel. What is recovery? A working definition from the Betty ford institute. J Subst Abus Treat. 2007;33:221–8. CrossRef
Goranitis I, Coast J, Day E, Copello A, Freemantle N, Frew E. Maximizing health or sufficient capability in economic evaluation? A methodological experiment of treatment for drug addiction. Med Decis Mak. 2017;37(5):498–511. CrossRef
Best D, Day E, Morgan B, Oza T, Copello A, Gossop M. What treatment means in practice: an analysis of the delivery of evidence-based structured interventions in criminal justice drug treatment services in Birmingham, England. Addict Res Theory. 2009;17(6):678–87. CrossRef
UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):541–4. CrossRef
UKATT Research Team. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):544–8. CrossRef
Dale V, Coulton S, Godfrey C, Copello A, Hodgson R, Heather N, Orford J, Raistrick D, Slegg G, Tober G, et al. Exploring treatment attendance and its relationship to outcome in a randomized controlled trial of treatment for alcohol problems: secondary analysis of the UK alcohol treatment trial (UKATT). Alcohol Alcohol. 2011;46(5):592–9. CrossRefPubMed
Dansereau DF, Simpson DD. A picture is worth a thousand words: the case for graphic representations. Prof Psychol. 2009;40(1):104–10. CrossRef
Day E. Building bridges to positive social identities: the social network diagram and opiate substitution treatment. In: Buckingham SA, Best D, editors. Addiction, Behavioural change and social identity. Abingdon: Routledge; 2017.
Day E, Best D, Bartholomew NG, Dansereau DF, Simpson DD. The BTEI care planning manual: mapping achievable goals. In: Routes to recovery. London: National Treatment Agency for Substance Misuse; 2008.
Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley & Sons; 1983.
Marsden J, Gossop M, Stewart D, Best D, Farrell M, Strang J. The Maudsley addiction profile: development and user manual. London: National Addiction Centre/Institute of Psychiatry; 1998.
Raistrick D, Tober G, Heather N, Clark JA. Validation of the social satisfaction questionnaire for outcome evaluation in substance use disorders. Psychiatr Bull. 2007;31:333–6. CrossRef
Heather N, Luce A, Peck D, Dunbar B, James I. Development of a treatment version of the readiness to change questionnaire. Addict Res. 1999;7(1):63–83. CrossRef
Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract Train. 1982;19(3):276–88. CrossRef
Cohen S, Mermelstein R, Kamarck T, Hoberman HM. Measuring the functional components of social support. In: Sarason IG, Sarason BR, editors. Measuring the functional components of social support. London: Springer; 1985. p. 73–94.
Joe GW, Broome KM, Rowan-Szal GA, Simpson DD. Measuring patient attributes and engagement in treatment. J Subst Abus Treat. 2002;22:183–96. CrossRef
SAS Institute Inc. Chapter 6: introduction to mixed Modelling procedures. In: SAS/STAT 92 User’s guide (second edition). Cary: SAS Institute Inc.; 2009. p. 127–40.
KO MG, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30–46. CrossRef
National Collaborating Centre for Mental Health. Drug misuse: psychosocial interventions. London: British Psychological Society & The Royal College of Psychiatrists; 2008.
Drummond C. Cuts to addiction services are a false economy. In: The bmj opinion, vol. 2017: BMJ; 2017.
AT ML, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, Gourevitch M, Stein J, Oros M, Horton T, et al. Can substance use disorders be managed using the chronic care model? Review and recommendations from a NIDA consensus group. Public Health Rev. 2013;35(2):8. CrossRef
White WL. Recovery management and recovery-oriented systems of care: scientific rationale and promising practices. Northeast Addiction Technology Transfer Center: Pittsburgh; 2008.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Fry-Smith A, Day E, Linzeris N, Roberts T, Burls A, et al. Methadone and Buprenorphine for the Management of Opioid Dependence: a systematic review and economic evaluation. Health Technol Assess. 2006;11(9):1–171.
Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, progress, services and outcomes. New York: Springer-Verlag; 1991. CrossRef
AT ML, Hagan TA, Levine M, Gould F, Meyers K, Bencivengo M, Durell J. Supplemental social services improve outcomes in public addiction treatment. Addiction. 1998;93(10):1489–99. CrossRef
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Coch Database Syst Rev. 2011;10:CD004147.
Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin LM, Gourevitch MN, Haller DL, et al. Adjunctive counseling during brief and extended Buprenorphine-Naloxone treatment for prescription Opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46. CrossRefPubMedPubMedCentral
Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, Poovendran D, Mitcheson L, Ryan F, Bowden-Jones O, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet. 2015;384(9938):153-63.
- A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services
Jennifer L. Seddon
- BioMed Central